Key result
Chemotherapy linked to active agonistic autoantibodies against alpha-1, M2, and Mas receptors in a cancer survivor.
Why the study?
Metabolic syndrome and cardiomyopathies develop long after chemo- and radiotherapy, suggesting autoimmune processes may contribute to these late effects.
Case Report (n=1)
The detection of agonistic autoantibodies in a cancer survivor suggests a potential autoimmune mechanism for late-onset chemotherapy-induced cardiomyopathies.
No takes yet. Share an insight, caveat, or question.
May suggest autoimmune contribution to late cardiotoxicity; hypothesis-generating and should not yet change practice.
Haberland et al. (2013) conducted a case report in Cancer survivor following chemotherapy treatment (n=1). Chemotherapy treatment was evaluated on Detection of functionally active agonistic autoantibodies. Functionally active agonistic autoantibodies against the adrenergic alpha1-receptor, muscarinic M2-receptor, and Mas-receptor were detected in the plasma of a cancer survivor following chemotherapy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: